产品
编 号：F493482
分子式：C24H35ClN2O5
分子量：467
分子式：C24H35ClN2O5
分子量：467
产品类型
规格
价格
是否有货
结构图
CAS No: 87725-72-2
产品详情
生物活性：
Trandolapril (RU44570) hydrochloride is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolapril hydrochlorideat. Trandolapril hydrochloride is an orally active angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI).
体内研究：
Trandolapril hydrochloride (3 mg/kg/day; p.o.; 7 d) reduces renal fibrosis in obstructive nephropathy in mice, by inhibiting renal interstitial matrix expression and myofibroblast activation, decreasing renal proinflammatory cytokine RANTES and TNF-α level.Trandolapril hydrochloride (0.3 mg/kg/day; p.o.; 4 weeks) improves arterial mechanics in rats, prevents arterial hypertrophy, collagen and cellular fibronectin accumulation.randolapril (0.3 mg/kg/day; p.o.; 4 months) exhibits a chronic anti-hypertension effects in rats, results in blood pressure decreasing.Trandolapril hydrochloride (0.25 mg/kg; p.o.; twice a day; 4 months) inhibits Atherosclerosis in the Watanabe Heritable Hyperlipidemic Rabbit.Animal Model:UUD (unilateral ureteral obstruction) model in Male CD-1 mice (18-22 g)
Dosage:3 mg/kg
Administration:Oral gavage; daily, for 7 days
Result:Resulted in renal interstitial matrix expression (including fibronectin, type I, and type III collagen) decreasing, and inhibited myofibroblast activation by surprising a-smooth muscle actin (a-SMA) expression, decreased the RANTES (regulated on activation, normal T cell expressed and secreted) and TNF-α level.
Animal Model:SHR model (spontaneously hypertensive rats, 4-week-old)
Dosage:0.3 mg/kg
Administration:Oral gavage; daily for 4 weeks
Result:Reduced collagen content in the aortic media and increased ariterial distensibility up to about 80%.
Animal Model:Watanabe heritable hyperlipidemic rabbit (3 months old)
Dosage:0.25 mg/kg
Administration:Oral gavage; twice a day; 9 months
Result:Decreased in atherosclerotic involvement of the intimal surface, and also decreased cholesterol content in descending thoracic aorta.
Trandolapril (RU44570) hydrochloride is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolapril hydrochlorideat. Trandolapril hydrochloride is an orally active angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI).
体内研究：
Trandolapril hydrochloride (3 mg/kg/day; p.o.; 7 d) reduces renal fibrosis in obstructive nephropathy in mice, by inhibiting renal interstitial matrix expression and myofibroblast activation, decreasing renal proinflammatory cytokine RANTES and TNF-α level.Trandolapril hydrochloride (0.3 mg/kg/day; p.o.; 4 weeks) improves arterial mechanics in rats, prevents arterial hypertrophy, collagen and cellular fibronectin accumulation.randolapril (0.3 mg/kg/day; p.o.; 4 months) exhibits a chronic anti-hypertension effects in rats, results in blood pressure decreasing.Trandolapril hydrochloride (0.25 mg/kg; p.o.; twice a day; 4 months) inhibits Atherosclerosis in the Watanabe Heritable Hyperlipidemic Rabbit.Animal Model:UUD (unilateral ureteral obstruction) model in Male CD-1 mice (18-22 g)
Dosage:3 mg/kg
Administration:Oral gavage; daily, for 7 days
Result:Resulted in renal interstitial matrix expression (including fibronectin, type I, and type III collagen) decreasing, and inhibited myofibroblast activation by surprising a-smooth muscle actin (a-SMA) expression, decreased the RANTES (regulated on activation, normal T cell expressed and secreted) and TNF-α level.
Animal Model:SHR model (spontaneously hypertensive rats, 4-week-old)
Dosage:0.3 mg/kg
Administration:Oral gavage; daily for 4 weeks
Result:Reduced collagen content in the aortic media and increased ariterial distensibility up to about 80%.
Animal Model:Watanabe heritable hyperlipidemic rabbit (3 months old)
Dosage:0.25 mg/kg
Administration:Oral gavage; twice a day; 9 months
Result:Decreased in atherosclerotic involvement of the intimal surface, and also decreased cholesterol content in descending thoracic aorta.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备